Tom Blackwell Email

VP, Information Technology . CTI BioPharma

Current Roles

Employees:
211
Revenue:
$32.7M
About
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. VONJO^TM is a trademark of CTI BioPharma Corp.
CTI BioPharma Address
3101 Western Ave., #600
Seattle, WA
United States
CTI BioPharma Email

Past Companies

CTI BioPharmaVice President, Information Technology
Center for Infectious Disease Research (formerly Seattle BioMed)Director, Information Technology
Walt Disney Internet Group (formerly Starwave Corp.)Director, Platform Systems & Hosting Infrastructure

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.